文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

非甾体抗炎药使用与Barrett食管风险降低无关

Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
PubMed 文献 · Am J Gastroenterol · 2016-08-30

该研究汇总BEACON联盟六项Barrett食管病例对照研究的个体数据,比较1,474例Barrett食管患者与2,256例人群对照及2,018例胃食管反流病对照的药物使用。规律使用任何非甾体抗炎药与Barrett食管风险无关(对人群对照调整OR=1.00,95%CI=0.76-1.32,I²=61%;对GERD对照调整OR=0.99,95%CI=0.82-1.19,I²=19%),阿司匹林或非阿司匹林非甾体抗炎药及最高频率、最长疗程使用亦无关联。

要点

  • 规律使用任何非甾体抗炎药与Barrett食管风险无关。
  • 阿司匹林或非阿司匹林非甾体抗炎药均未见关联。
  • 最高频率(至少每日)和最长疗程(≥5年)使用亦无关联。

核心结论

  • 非甾体抗炎药使用与Barrett食管风险无关。
  • 既往报道的非甾体抗炎药与食管腺癌的负相关可能通过降低Barrett食管患者肿瘤进展风险实现。

研究设计与样本

  • 分析Barrett食管和食管腺癌联盟(BEACON)六项Barrett食管病例对照研究的汇总个体水平参与者数据。
  • 比较1,474例Barrett食管患者与2,256例人群对照及2,018例胃食管反流病(GERD)对照的药物使用。
  • 研究特异性比值比(OR)和95%置信区间(CI)采用多变量逻辑回归模型估计,并用随机效应Meta分析模型合并。

主要发现

  • 规律(至少每周一次)使用任何非甾体抗炎药与Barrett食管风险无关(对人群对照,调整OR=1.00,95%CI=0.76-1.32,I²=61%;对GERD对照,调整OR=0.99,95%CI=0.82-1.19,I²=19%)。
  • 在服用阿司匹林或非阿司匹林非甾体抗炎药的个体中观察到类似的无效结果。
  • 最高频率(至少每日使用)和最长疗程(≥5年)的非甾体抗炎药使用亦无关联。
  • 存在中度研究间异质性证据;但在「留一法」敏感性分析中,非甾体抗炎药使用的关联仍无统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在中度研究间异质性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of esophageal adenocarcinoma. Epidemiological studies examining the association between NSAID use and the risk of the precursor lesion, Barrett's esophagus, have been inconclusive. METHODS: We analyzed pooled individual-level participant data from six case-control studies of Barrett's esophagus in the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). We compared medication use from 1,474 patients with Barrett's esophagus separately with two control groups: 2,256 population-based controls and 2,018 gastroesophageal reflux disease (GERD) controls. Study-specific odds ratio (OR) and 95% confidence intervals (CI) were estimated using multivariable logistic regression models and were combined using a random-effects meta-analytic model. RESULTS: Regular (at least once weekly) use of any NSAIDs was not associated with the risk of Barrett's esophagus (vs. population-based controls, adjusted OR=1.00, 95% CI=0.76-1.32, I2=61%; vs. GERD controls, adjusted OR=0.99, 95% CI=0.82-1.19, I2=19%). Similar null findings were observed among individuals who took aspirin or non-aspirin NSAIDs. We also found no association with highest levels of frequency (at least daily use) and duration (≥5 years) of NSAID use. There was evidence of moderate between-study heterogeneity; however, associations with NSAID use remained non-significant in "leave-one-out" sensitivity analyses. CONCLUSIONS: Use of NSAIDs was not associated with the risk of Barrett's esophagus. The previously reported inverse association between NSAID use and esophageal adenocarcinoma may be through reducing the risk of neoplastic progression in patients with Barrett's esophagus.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Thrift AP, Anderson LA, Murray LJ, et al. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016. PMID: 27575711. doi:10.1038/ajg.2016.348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。